The vTv Therapeutics Inc (VTVT) Downgraded by Zacks Investment Research to “Hold”

The vTv Therapeutics Inc (VTVT) Downgraded by Zacks Investment Research to “Hold”

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Zacks Investment Research downgraded shares of vTv Therapeutics Inc (NASDAQ:VTVT) from a buy rating to a hold rating in a research report report published on Tuesday.

vTv Therapeutics (NASDAQ VTVT) opened at 5.00 on Tuesday. The company’s market capitalization is $48.47 million. The company has a 50 day moving average of $5.25 and a 200 day moving average of $5.53. vTv Therapeutics has a 1-year low of $4.65 and a 1-year high of $7.50. vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.20 million. On average, analysts predict that vTv Therapeutics will post ($1.15) earnings per share for the current fiscal year.

In related news, Director Paul G. Savas purchased 10,000 shares of the stock in a transaction that occurred on Friday, March 31st. The stock was acquired at an average cost of $6.50 per share, with a total value of $65,000.00. Following the transaction, the director now owns 66,435 shares of the company’s stock, valued at approximately $431,827.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock. Several large investors have recently made changes to their positions in VTVT. Sphera Funds Management LTD. raised its stake in shares of vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock valued at $1,965,000 after buying an additional 100,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of vTv Therapeutics by 0.3% in the first quarter. Vanguard Group Inc. now owns 289,391 shares of the biotechnology company’s stock valued at $1,896,000 after buying an additional 932 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in shares of vTv Therapeutics by 31.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 213,200 shares of the biotechnology company’s stock valued at $1,030,000 after buying an additional 51,301 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of vTv Therapeutics during the first quarter valued at about $917,000. Finally, Renaissance Technologies LLC raised its stake in shares of vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 2,900 shares in the last quarter. 12.18% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VTVT”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment